New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
07:09 EDTRTRXRetrophin raises FY14 revenue view to $19M-$21M from $10M-$12M
One estimate $11M. Raises FY15 revenue view to $35M-$40M from $19M-$21M, one estimate $20M. Retrophin CEO Martin Shkreli said, “Reimbursement of Chenodal has remained robust, and initial efforts to find undiagnosed cerebrotendinous xanthomatosis patients are promising. We have raised our guidance for 2014 and 2015 revenue accordingly. We are very comfortable with our current cash balance and future obligations. The success of Chenodal significantly reduces our cash needs and may propel the company to profitability in the near-term. As such, we have no need or desire to explore a dilutive equity offering unless it is accompanied by an accretive and strategic acquisition. Retrophin remains opportunistic with respect to M&A and has strong access to both debt and equity capital.”
News For RTRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 17, 2015
09:12 EDTRTRXRetrophin management to meet with Leerink
Subscribe for More Information
November 16, 2015
08:09 EDTRTRXRetrophin receives EU ODD for sparsentan
Retrophin announced that the European Commission, or EC, has granted sparsentan orphan drug designation for the treatment of focal segmental glomerulosclerosis, or FSGS. Retrophin previously announced in January 2015 that sparsentan received orphan drug designation from the FDA for the treatment of FSGS. Sparsentan is the company's investigational therapeutic agent which acts as both a potent angiotensin receptor blocker, as well as a selective endothelin receptor antagonist, and is currently being evaluated in the Phase 2 DUET trial in FSGS patients. FSGS is a widely recognized cause of end-stage renal disease and there are no approved pharmacologic treatments currently available in the United States or Europe.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use